A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Julie N GraffTomasz M BeerJoshi J AlumkalRachel E SlottkeWilliam L RedmondGeorge V ThomasReid F ThompsonMary A WoodYoshinobu KoguchiYiyi ChenEmile LatourRaymond C BerganCharles G DrakeAmy E MoranPublished in: Journal for immunotherapy of cancer (2021)
clinicaltrials.gov (NCT02312557).